sin-a-KAL-set 
Contraindicated in:
Use Cautiously in:
CV: HF exacerbation, QT interval prolongation, ARRHYTHMIA, hypotension, TORSADES DE POINTES.
F and E: HYPOCALCEMIA.
Metab: adynamic bone disease.
Neuro: SEIZURES.
Drug-Drug:
Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis
Parathyroid Carcinoma or Primary Hyperparathyroidism
Absorption: Well absorbed following oral administration; absorption is enhanced by food and further enhanced by a high-fat meal.
Distribution: Extensively distributed to tissues.
Protein Binding: 93–97%.
Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4, CYP2D6, and CYP1A2 isoenzymes; 80% excreted in urine as metabolites, 15% in feces.
Half-life: 30–40 hr.
NDC Code*